SYNTHESIS AND RING CLEAVAGE OF A STERICALLY HINDERED TETRAHYDRO-4H-FURO [2,3-b]PYRAN-2-ONE. A MODEL FOR THE TOTAL SYNTHESIS OF BLEPHAROCALYXIN E

Sidika Polat Cakir and Keith T. Mead* Department of Chemistry, Mississippi State University, Mississippi State, Mississippi 39762, USA E-mail: kmead@ra.msstate.edu

Abstract: A synthesis of 4-(2,4,6-trimethoxyphenyl)-3,4-dihydro-2*H*-pyran from 2,4,6-trimethoxybenzaldehyde is reported. Radical induced cycloaddition of potassium monomethyl malonate (PMMM) to this dihydropyran has been demonstrated to give a bicyclic lactone as a single isomer. Subsequent alpha aryl substitution, ring cleavage, and rearrangement steps provided a *C*-aryl pyranoside derivative which represents a model for the total synthesis of blepharocalyxin E.

Introduction

A number of diarylheptanoid constituents of *Alpinia blepharocalyx* have been isolated and identified by Kadota and coworkers and shown to exhibit significant antiproliferative activity against human fibrosarcoma HT-1080 and murine colon 26-L5 carcinoma cells *in vitro*.¹⁻³ One of these constituents, blepharocalyxin E 1, was first reported in 2000.³ A synthetic plan for this compound was developed by our group which was based on the observation that simple tetrahydro-4H-furo[2,3-b]pyran-2-ones such as compound 2 (Scheme 1) could be cleaved with electron rich aromatic nucleophiles to give *C*aryl pyranosides as single isomers.^{4,5} The generality of this method, however, has not been put to the test. Specifically, the question remained as to whether more complex derivatives of compound 2 bearing bulkier trialkoxyphenyl substitution in place of phenyl could be prepared and ring cleaved with the same efficiency. Given that this would be a requirement for C5-substitution in the natural product 1, a study was initiated to answer this question.



Results

We have previously reported a route to *exo*-substituted tetrahydro-4H-furo[2,3-b]pyran-2-ones such as compound **2** by radical induced cycloaddition of potassium monomethyl malonate (PMMM) to 4-substituted dihydropyrans.⁵ Related reactions had previously been reported independently by the groups of Trogolo⁶ and Currie⁷, but prior to our work reactions of PMMM with 4-substituted dihydropyrans had not been reported. For our present study we required 4-(2,4,6-trimethoxyphenyl)-

3,4-dihydro-2*H*-pyran 9 (Scheme 2), which had not been reported in the literature. Starting from commercially available 2,4,6-trimethoxybenzaldehyde, conversion to alcohol 4 was achieved in two steps by Horner-Emmons olefination followed by standard reduction of ester 3. A Claisen rearrangement from vinyl ether 5 provided alcohol 6, which was converted to dihydropyran 9, via diol 7 and lactone 8, in four steps.



^aConditions and reagents: (a) (MeO)₂POCH₂CO₂Me, LHMDS, 0°C, 2h (98%); (b) DIBAL-H, toluene, 0°C, 3h (94%); (c) CH₂=CHOEt, Hg(OAc)₂, reflux 12h (91%); (d) iBu₃Al, CH₂Cl₂, 0°C, 45 min (66%); (e) (i) BH₃SMe₂; (ii) NaOH, H₂O₂, THF, 0°C, 3h (98%); (f) PCC, CH₂Cl₂, 4 A° crushed mol. sieves, 0°C - rt, 12h (56%); (g) (i) DIBAL-H, -78°C, 1h (89%); (ii) MsCl, pyridine, 0°C, 2h (64%). Scheme-2^a

With compound 9 in hand, conversion to bicyclic lactone 10, as a single isomer in moderate yield, was achieved by reaction with potassium monomethyl malonate in the presence of ceric ammonium nitrate (CAN)⁶ (Scheme 3). The stereochemistry of compound 10 was verified by x-ray crystallography. For the alpha-arylation of compound 10, we turned to the use of aryllead (IV) triacetates, as described by Pinhey⁸ and, more recently, Konopelski.⁹ Initially this proved to be a little problematic, but was finally solved by treatment of 10 with 4-methoxyphenyllead triacetate in the presence of 1,10-phenanthroline, which gave compound 11 as a single isomer. Numerous conditions were studied for the decarboxylation of intermediate 11. The best results were found using Lil in DMF, which gave lactone 12 as a 16:1 separable mixture (*exo:endo*) of diastereomers. As expected, reaction of lactone 12 with TiCl₄ and anisole did not provide the desired product 14, but instead gave butyrolactone 13. Fortunately, this rearranged to the methyl ester 14 on exposure to dry methanolic HCl. The stereochemical assignments of compounds 13 and 14 were supported by both 1-D (¹H, ¹³C)¹⁰ and 2-D (HETCOR) NMR experiments, and by comparison with related derivatives previously prepared in our lab.^{4,5}

Heterocyclic Communications



^aConditions and reagents: (a) PMMM, CAN, CH₃CN, rt 45 min (59%); (b) 4-methoxyphenyllead triacetate, 1,10-phenanthroline, CHCl₃, reflux 24h (85%); (c) LiI, DMF, reflux 5h (67%); (d) TiCl₄, anisole, CH₂Cl₂, -10 to -15°C, 2h (83%); (e) 5% dry HCl, MeOH, rt 5h (94%). Scheme-3^a

The formation of compound 13 from intermediate 12 was not unexpected. Earlier work in our lab had shown that alpha-substituted bicyclic lactones give butyrolactone products under these conditions.^{4,5} Importantly, compound 13 is believed to arise from equilibration of the first-formed acid 15, rather than from direct substitution of lactone 12 (Scheme 4). This reasoning is based on the results of ring opening reactions of alpha-unsubstituted derivatives, which give *C*-aryl pyranosides directly (see Scheme 1), coupled with the rationale that the acyl C-O bond in compound 12 is clearly more prone to cleavage than the ether C-O bond. Presumably the rearrangement $(15 \rightarrow 13)$ is driven by the steric interaction between the substituent alpha to the carboxylic acid moiety (Ar²) and the C2-substituent on the tetrahydropyran ring.



Conclusions

The formation of an *exo*-substituted tetrahydro-4H-furo[2,3-b]pyran-2-one using the previously reported protocol has been shown to be tolerated by the presence of a bulky 2,4,6-trimethoxyphenyl substituent at the 4-position on the dihydropyran ring. Moreover, subsequent alpha-arylation and ring cleavage reactions of the bicyclic lactone have been shown to proceed without incident. This result bodes well for the total synthesis of blepharocalyxin E and its related analogues using this strategy.

References

- 1. M. S. Ali, A. H. Banskota, Y. Tezuka, I. Saiki, S. Kadota, *Biol. Pharm. Bull.* 24, 525-528 (2001).
- 2. M. B. Gewali, Y. Tezuka, A. H. Banskota, M. S. Ali, I. Saiki, H. Dong, S. Kadota, Org. Lett. 1, 1733-1736 (1999).
- 3. Y. Tezuka, M. S. Ali, A. H. Banskota, S. Kadota, Tetrahedron Lett. 41, 5903-5907 (2000).
- 4. S. P. Cakir, K. T. Mead, L. Smith, Tetrahedron Lett. 44, 6355-6358 (2003).
- 5. S. P. Cakir, K. T. Mead, J. Org. Chem. 69, 2203-2205 (2004).
- 6. A. D'Annibale, C. Trogolo, Tetrahedron Lett. 35, 2083-2086 (1994).
- 7. M. del Rosario-Chow, J. Ungwitayatorn, B. L. Currie, Tetrahedron Lett. 32, 1011-1014 (1991).
- 8. J. T. Pinhey, B. A. Rowe, Aust. J. Chem. 33, 113-120 (1980).
- 9. H. Deng, J. P. Konopelski, Org. Lett. 3, 3001-3004 (2001).
- Spectral data for compound 14: ¹H NMR (CDCl₃, 300 MHz): δ 7.12 (d, J=8.8 Hz, 2H), 6.67 (d, J=8.6 Hz, 2H), 6.55 (d, J=8.8 Hz, 2H), 6.46 (d, J=8.8 Hz, 2H), 6.14 (s, 1H), 6.06 (s, 1H), 4.52 (d, J=9.5 Hz, 1H), 3.94 (s, 5H), 3.80 (s, 3H), 3.78 (s, 3H), 3.75 (s, 3H), 3.69 (s, 3H), 3.64-3.5 (m, 3H), 3.34 (s, 3H), 2.47 (qd, J=12.7, 4.6 Hz, 1H), 1.50 (d(broad), J=11.6 Hz, 1H); ¹³C NMR (CDCl₃, 75 MHz): δ 173.3, 159.7, 159.0, 157.6, 133.1, 130.0, 129.76, 129.70, 113.3, 112.7, 112.1, 91.2, 90.5, 83.6, 68.9, 55.5, 55.2, 55.1, 51.4, 51.1, 46.2, 35.5, 31.3; FT-IR (CHCl₃): 2946, 2837, 1733, 1608, 1513, 1250, 1153, 1127, 734; R_f: 0.41 (Hexane: EtOAc; 1:1); Melting Point: 130-132°C.

Received on September 09, 2005